Foundayo and Sleep Apnea in 2026: Lilly's GLP-1 Pill Cut Breathing Interruptions by Nearly Half in a New Trial

ATTAIN-OSA was really two parallel studies with 712 adults in total, all with moderate-to-severe obstructive sleep apnea and a BMI of 27 or higher. One study enrolled 363 people who were not using a PAP machine (the familiar CPAP mask); the other enrolled 349 people who were already on PAP therapy. Everyone took either Foundayo or a placebo once a day for 52 weeks, according to the American Heart Association's summary of the trial.

The headline measure in sleep apnea research is the apnea-hypopnea index, or AHI — how many times per hour your breathing stops or becomes dangerously shallow during sleep. People in the trial started out severe, averaging roughly 50 to 58 events every hour.

After a year, people taking Foundayo who were not on a PAP machine saw their AHI drop by 21.1 events per hour — a 43.8% reduction — compared with a drop of just 4.3 events per hour on placebo. Among PAP users, the pill cut AHI by 18.3 events per hour versus 5.5 on placebo. Nearly half (47.2%) of non-PAP participants on the pill cut their breathing interruptions by at least half, and 31.5% improved all the way to remission or mild disease — close to one in three.

Sleep apnea is closely tied to cardiovascular disease, which is why these results debuted at a heart conference. Alongside the breathing improvements, participants taking Foundayo lost about 11% of their body weight — roughly 28 pounds on average — compared with 1–2% on placebo. Their systolic blood pressure fell by about 7 to 9 mmHg, and hsCRP, a blood marker of inflammation, dropped by roughly 39–49% depending on the study arm.

Those secondary numbers matter because untreated sleep apnea doesn't just ruin your sleep and your partner's. The repeated oxygen drops stress the heart night after night, raising the risk of high blood pressure, heart attack, stroke, and atrial fibrillation. A treatment that improves breathing, weight, blood pressure, and inflammation at the same time is addressing the whole cluster.

No GLP-1 medication is side-effect-free, and Foundayo is no exception. The most common problems in ATTAIN-OSA were gastrointestinal — nausea, diarrhea, constipation, indigestion, and vomiting — mostly mild to moderate, and most noticeable while the dose is being increased. In the non-PAP study, 12.2% of people on the pill stopped treatment because of side effects, versus 3.8% on placebo.

Those numbers are consistent with what we see across the GLP-1 class, and most patients can manage the stomach effects with slower dose escalation, smaller meals, and sometimes anti-nausea support. GLP-1s also carry screening considerations — they're not appropriate for people with a personal or family history of medullary thyroid cancer or MEN2, for example, and a history of pancreatitis warrants a conversation. This is exactly why these medications require a prescription and a licensed provider who reviews your history first.

Foundayo would not be the first GLP-1 approved for sleep apnea — Zepbound (tirzepatide), a weekly injection, earned that approval first, and the experimental triple-agonist retatrutide posted strong sleep apnea results earlier this fall. What's new here is the format: a daily pill, with no injections and no refrigeration, that can be manufactured at scale.

That matters for access. Obstructive sleep apnea is one of the most common — and most undertreated — sleep disorders, and many people simply never adjust to sleeping with a CPAP mask. To be clear, the trial doesn't show the pill replaces CPAP — PAP users in the study improved on top of their machine therapy, and CPAP remains the standard first-line treatment. But for people with obesity-driven sleep apnea who can't or won't use a mask, a once-daily tablet that cuts breathing interruptions by more than 40% is a meaningful new option.

Foundayo is already FDA-approved for chronic weight management, so providers can prescribe it today for weight loss — the sleep apnea indication is what Lilly is now taking to the FDA. On the self-pay side, the lowest dose runs $149 per month through LillyDirect, with commercially insured patients paying as little as $25 a month with a savings card — pricing that has helped the pill move quickly into telehealth and pharmacy channels since launch.

If the FDA approves the sleep apnea indication in 2027, insurance coverage could broaden further, since insurers often treat sleep apnea as a distinct medical necessity from weight management alone.

If you're carrying extra weight and snoring heavily, waking up gasping, or dragging through your days exhausted, don't guess — those are classic sleep apnea signs, and the condition is very treatable. A licensed provider can help you sort out whether a sleep study, a GLP-1 medication, or both belong in your plan.

JoeyMed's weight loss program connects you with a licensed provider online who reviews your health history, screens for contraindications, and builds a treatment plan around your goals — including GLP-1 options like compounded tirzepatide where clinically appropriate. Visit JoeyMed Weight Loss to take the first step from your couch, no waiting room required.

This article is for informational purposes only and is not medical advice. Treatment decisions, including whether a GLP-1 medication is right for you, should always be made with a licensed healthcare provider.